[{"id":"b58e8f18-6ad1-49e6-929a-a6948bafdb8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04447716","created_at":"2021-01-18T21:24:06.674Z","updated_at":"2024-07-02T16:34:27.618Z","phase":"Phase 1","brief_title":"An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment","source_id_and_acronym":"NCT04447716","lead_sponsor":"Thomas Jefferson University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Riabni (rituximab-arrx)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/16/2020","start_date":" 10/16/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-06-10"},{"id":"18ee0f81-3adf-4bd7-8334-4d0c4101af0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05886036","created_at":"2023-11-15T20:15:29.821Z","updated_at":"2024-07-02T16:35:07.221Z","phase":"Phase 2","brief_title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma","source_id_and_acronym":"NCT05886036","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • PD-1 • PD-L2","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • PD-1 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Lunsumio (mosunetuzumab-axgb) • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/23/2024","start_date":" 01/23/2024","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2024-04-29"},{"id":"b7e05237-c123-498d-b356-0eff2ae8d36b","acronym":"ACE-LY-308","url":"https://clinicaltrials.gov/study/NCT02972840","created_at":"2021-01-18T14:36:50.624Z","updated_at":"2024-07-02T16:35:15.640Z","phase":"Phase 3","brief_title":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","source_id_and_acronym":"NCT02972840 - ACE-LY-308","lead_sponsor":"Acerta Pharma BV","biomarkers":" CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase) • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 635","initiation":"Initiation: 04/05/2017","start_date":" 04/05/2017","primary_txt":" Primary completion: 10/28/2025","primary_completion_date":" 10/28/2025","study_txt":" Completion: 10/28/2025","study_completion_date":" 10/28/2025","last_update_posted":"2024-03-08"},{"id":"60e63980-bc0c-401e-a0fc-6fabe46bb034","acronym":"","url":"https://clinicaltrials.gov/study/NCT03623373","created_at":"2021-01-18T17:48:07.465Z","updated_at":"2025-02-25T15:07:50.049Z","phase":"Phase 2","brief_title":"Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT03623373","lead_sponsor":"Washington University School of Medicine","biomarkers":" CCND1 • CD34","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase) • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 11/29/2018","start_date":" 11/29/2018","primary_txt":" Primary completion: 02/09/2020","primary_completion_date":" 02/09/2020","study_txt":" Completion: 02/05/2025","study_completion_date":" 02/05/2025","last_update_posted":"2024-02-13"},{"id":"bac456cb-b78b-4934-9ea0-909a41338c0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659044","created_at":"2021-01-19T20:42:10.154Z","updated_at":"2024-07-02T16:35:24.240Z","phase":"Phase 2","brief_title":"Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT04659044","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 04/01/2021","start_date":" 04/01/2021","primary_txt":" Primary completion: 04/04/2027","primary_completion_date":" 04/04/2027","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2024-01-08"},{"id":"c44e1bba-0f58-4353-9a63-af5f285a4ca4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04660799","created_at":"2021-01-19T20:42:31.361Z","updated_at":"2024-07-02T16:35:33.844Z","phase":"Phase 2","brief_title":"A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT04660799","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Rituxan Hycela (rituximab/hyaluronidase) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":" Primary completion: 05/23/2022","primary_completion_date":" 05/23/2022","study_txt":" Completion: 10/11/2022","study_completion_date":" 10/11/2022","last_update_posted":"2023-10-12"},{"id":"2f7674d9-be91-409b-a78a-efea8c41ee23","acronym":"","url":"https://clinicaltrials.gov/study/NCT01808599","created_at":"2021-01-18T08:01:12.475Z","updated_at":"2024-07-02T16:35:47.649Z","phase":"Phase 2","brief_title":"Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma","source_id_and_acronym":"NCT01808599","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukeran (chlorambucil) • Rituxan Hycela (rituximab/hyaluronidase)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2023-05-18"},{"id":"ad933d2d-1e5b-4cef-a00f-9e0a20a57e30","acronym":"MALIBU","url":"https://clinicaltrials.gov/study/NCT03697512","created_at":"2021-01-18T18:07:19.554Z","updated_at":"2024-07-02T16:35:48.380Z","phase":"Phase 2","brief_title":"MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas","source_id_and_acronym":"NCT03697512 - MALIBU","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • Rituxan Hycela (rituximab/hyaluronidase)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 175","initiation":"Initiation: 09/27/2019","start_date":" 09/27/2019","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 06/15/2027","study_completion_date":" 06/15/2027","last_update_posted":"2023-05-10"},{"id":"9f42d0cd-4008-444e-b870-ed10007d979e","acronym":"FLIRT","url":"https://clinicaltrials.gov/study/NCT02303119","created_at":"2021-01-18T10:53:28.954Z","updated_at":"2024-07-02T16:35:57.854Z","phase":"Phase 3","brief_title":"Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)","source_id_and_acronym":"NCT02303119 - FLIRT","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Rituxan Hycela (rituximab/hyaluronidase)"],"overall_status":"Completed","enrollment":" Enrollment 221","initiation":"Initiation: 02/02/2015","start_date":" 02/02/2015","primary_txt":" Primary completion: 06/29/2021","primary_completion_date":" 06/29/2021","study_txt":" Completion: 06/29/2021","study_completion_date":" 06/29/2021","last_update_posted":"2023-01-10"},{"id":"450e9b3f-21de-46fe-b09b-0c67d9472df1","acronym":"PTLD-2","url":"https://clinicaltrials.gov/study/NCT02042391","created_at":"2021-01-18T09:22:46.569Z","updated_at":"2024-07-02T16:36:04.849Z","phase":"Phase 2","brief_title":"Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy","source_id_and_acronym":"NCT02042391 - PTLD-2","lead_sponsor":"Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • oxaliplatin • prednisone • dexamethasone • Rituxan Hycela (rituximab/hyaluronidase) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 02/03/2015","start_date":" 02/03/2015","primary_txt":" Primary completion: 07/13/2021","primary_completion_date":" 07/13/2021","study_txt":" Completion: 07/13/2022","study_completion_date":" 07/13/2022","last_update_posted":"2022-08-25"},{"id":"f9dd3232-053b-4ab6-a701-4d357a206174","acronym":"","url":"https://clinicaltrials.gov/study/NCT02406092","created_at":"2021-01-18T11:29:18.050Z","updated_at":"2024-07-02T16:36:23.633Z","phase":"Phase 3","brief_title":"Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A","source_id_and_acronym":"NCT02406092","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • fludarabine IV • Rituxan Hycela (rituximab/hyaluronidase) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 122","initiation":"Initiation: 10/13/2015","start_date":" 10/13/2015","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2021-09-30"},{"id":"0b6f1f44-2d38-4c85-bd26-ca83a3aba7eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02128061","created_at":"2021-01-18T09:51:51.366Z","updated_at":"2024-07-02T16:36:31.994Z","phase":"Phase 3","brief_title":"Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+","source_id_and_acronym":"NCT02128061","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" CD20 • MME","pipe":"","alterations":" ","tags":["CD20 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • Rituxan Hycela (rituximab/hyaluronidase)"],"overall_status":"Completed","enrollment":" Enrollment 250","initiation":"Initiation: 08/01/2014","start_date":" 08/01/2014","primary_txt":" Primary completion: 11/05/2018","primary_completion_date":" 11/05/2018","study_txt":" Completion: 01/01/2021","study_completion_date":" 01/01/2021","last_update_posted":"2021-04-13"},{"id":"c9c56c2d-edb1-4c5b-929e-e4756bcd2a04","acronym":"","url":"https://clinicaltrials.gov/study/NCT01889069","created_at":"2021-01-18T08:28:53.127Z","updated_at":"2024-07-02T16:36:42.016Z","phase":"Phase 3","brief_title":"A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)","source_id_and_acronym":"NCT01889069","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • bendamustine • Rituxan Hycela (rituximab/hyaluronidase)"],"overall_status":"Completed","enrollment":" Enrollment 159","initiation":"Initiation: 07/31/2013","start_date":" 07/31/2013","primary_txt":" Primary completion: 05/28/2019","primary_completion_date":" 05/28/2019","study_txt":" Completion: 05/28/2019","study_completion_date":" 05/28/2019","last_update_posted":"2020-08-13"},{"id":"7fae547a-7c19-4e71-9529-e3ee74ffbf66","acronym":"","url":"https://clinicaltrials.gov/study/NCT01461928","created_at":"2021-01-18T06:04:49.996Z","updated_at":"2024-07-02T16:36:57.271Z","phase":"Phase 3","brief_title":"A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab","source_id_and_acronym":"NCT01461928","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Rituxan Hycela (rituximab/hyaluronidase)"],"overall_status":"Completed","enrollment":" Enrollment 692","initiation":"Initiation: 12/20/2011","start_date":" 12/20/2011","primary_txt":" Primary completion: 06/02/2018","primary_completion_date":" 06/02/2018","study_txt":" Completion: 06/02/2018","study_completion_date":" 06/02/2018","last_update_posted":"2019-08-06"},{"id":"68a89796-5a48-4fc6-97e5-98ff979dc809","acronym":"B-R-ENDA","url":"https://clinicaltrials.gov/study/NCT01686321","created_at":"2021-01-18T07:18:53.703Z","updated_at":"2024-07-02T16:37:04.340Z","phase":"Phase 2","brief_title":"Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma","source_id_and_acronym":"NCT01686321 - B-R-ENDA","lead_sponsor":"University of Göttingen","biomarkers":" ALK • CD20","pipe":" | ","alterations":" ALK positive","tags":["ALK • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 07/04/2012","start_date":" 07/04/2012","primary_txt":" Primary completion: 08/08/2018","primary_completion_date":" 08/08/2018","study_txt":" Completion: 08/08/2018","study_completion_date":" 08/08/2018","last_update_posted":"2018-12-31"},{"id":"5d558153-0d77-4a7d-bafb-48a4cf96e0c6","acronym":"MabRella","url":"https://clinicaltrials.gov/study/NCT01987505","created_at":"2021-01-18T09:03:36.215Z","updated_at":"2024-07-02T16:37:04.401Z","phase":"Phase 3","brief_title":"MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma","source_id_and_acronym":"NCT01987505 - MabRella","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Rituxan Hycela (rituximab/hyaluronidase)"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 11/11/2013","start_date":" 11/11/2013","primary_txt":" Primary completion: 04/11/2017","primary_completion_date":" 04/11/2017","study_txt":" Completion: 04/11/2017","study_completion_date":" 04/11/2017","last_update_posted":"2018-12-26"},{"id":"9f5c6f90-e358-4d2a-b4d7-8fabe7b26138","acronym":"","url":"https://clinicaltrials.gov/study/NCT01200758","created_at":"2021-01-18T04:48:42.228Z","updated_at":"2024-07-02T16:37:05.044Z","phase":"Phase 3","brief_title":"A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT01200758","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Rituxan Hycela (rituximab/hyaluronidase) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 410","initiation":"Initiation: 02/15/2011","start_date":" 02/15/2011","primary_txt":" Primary completion: 06/12/2012","primary_completion_date":" 06/12/2012","study_txt":" Completion: 10/31/2017","study_completion_date":" 10/31/2017","last_update_posted":"2018-11-27"},{"id":"a4adadfa-b495-4990-aae8-c9279933f7ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT01724021","created_at":"2021-01-18T07:31:40.565Z","updated_at":"2024-07-02T16:37:14.628Z","phase":"Phase 3","brief_title":"A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a","source_id_and_acronym":"NCT01724021","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • bendamustine • Rituxan Hycela (rituximab/hyaluronidase) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 743","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 01/01/2015","primary_completion_date":" 01/01/2015","study_txt":" Completion: 01/01/2015","study_completion_date":" 01/01/2015","last_update_posted":"2018-01-23"},{"id":"bf1e695b-55ff-45f1-8c16-25552871b59f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01649856","created_at":"2021-01-18T07:06:26.494Z","updated_at":"2024-07-02T16:37:17.189Z","phase":"Phase 3","brief_title":"A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT01649856","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Rituxan Hycela (rituximab/hyaluronidase)"],"overall_status":"Completed","enrollment":" Enrollment 572","initiation":"Initiation: 08/24/2012","start_date":" 08/24/2012","primary_txt":" Primary completion: 10/21/2014","primary_completion_date":" 10/21/2014","study_txt":" Completion: 09/16/2016","study_completion_date":" 09/16/2016","last_update_posted":"2017-10-11"},{"id":"cbcaa797-8799-452e-ac31-ef864802eba5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00366418","created_at":"2021-01-18T01:16:20.565Z","updated_at":"2024-07-02T16:37:20.257Z","phase":"Phase 1","brief_title":"Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT00366418","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Rituxan Hycela (rituximab/hyaluronidase)"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 08/10/2006","start_date":" 08/10/2006","primary_txt":" Primary completion: 06/11/2009","primary_completion_date":" 06/11/2009","study_txt":" Completion: 06/11/2009","study_completion_date":" 06/11/2009","last_update_posted":"2017-07-02"},{"id":"2a892432-8ba6-4497-8ead-6a5e2b218bef","acronym":"","url":"https://clinicaltrials.gov/study/NCT00930514","created_at":"2021-01-18T03:36:12.437Z","updated_at":"2024-07-02T16:37:27.833Z","phase":"Phase 1","brief_title":"A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma","source_id_and_acronym":"NCT00930514","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Rituxan Hycela (rituximab/hyaluronidase)"],"overall_status":"Completed","enrollment":" Enrollment 281","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 07/01/2013","study_completion_date":" 07/01/2013","last_update_posted":"2016-11-02"},{"id":"3b2f958e-ccca-4e80-817e-0892f3e29469","acronym":"","url":"https://clinicaltrials.gov/study/NCT02199288","created_at":"2021-01-18T10:17:02.253Z","updated_at":"2024-07-02T16:37:27.885Z","phase":"","brief_title":"Effectiveness, Safety \u0026 Nurse Management Study of MabThera SC in Patients With Non-Hodgkin's Lymphoma: Real-Life Setting","source_id_and_acronym":"NCT02199288","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Rituxan Hycela (rituximab/hyaluronidase)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 08/01/2014","start_date":" 08/01/2014","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 07/01/2016","study_completion_date":" 07/01/2016","last_update_posted":"2016-11-02"},{"id":"8aca0298-c07e-47e7-935a-47a5ab01e2f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00330252","created_at":"2021-01-18T01:08:23.508Z","updated_at":"2024-07-02T16:37:32.187Z","phase":"Phase 1","brief_title":"Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL","source_id_and_acronym":"NCT00330252","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CCND1 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • Rituxan Hycela (rituximab/hyaluronidase)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 05/01/2006","start_date":" 05/01/2006","primary_txt":" Primary completion: 01/01/2013","primary_completion_date":" 01/01/2013","study_txt":" Completion: 01/01/2014","study_completion_date":" 01/01/2014","last_update_posted":"2016-05-13"},{"id":"4fb75470-4369-419c-a369-d8494156cd6e","acronym":"PTL","url":"https://clinicaltrials.gov/study/NCT02753062","created_at":"2021-01-18T13:29:51.160Z","updated_at":"2024-07-02T16:37:32.500Z","phase":"Phase 2","brief_title":"Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT02753062 - PTL","lead_sponsor":"Asan Medical Center","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase)"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2016-04-27"}]